Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Change in Account Payables (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Change in Account Payables for 6 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 7.06% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $977000.0 through Dec 2025, down 38.32% year-over-year, with the annual reading at $977000.0 for FY2025, 38.32% down from the prior year.
  • Change in Account Payables for Q4 2025 was $1.7 million at Janux Therapeutics, up from -$168000.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $2.6 million in Q3 2021, with the low at -$1.6 million in Q1 2025.
  • Average Change in Account Payables over 5 years is $234150.0, with a median of $58000.0 recorded in 2022.
  • The sharpest move saw Change in Account Payables surged 5642.22% in 2021, then crashed 326.17% in 2024.
  • Over 5 years, Change in Account Payables stood at -$482000.0 in 2021, then surged by 146.27% to $223000.0 in 2022, then surged by 46.64% to $327000.0 in 2023, then soared by 376.76% to $1.6 million in 2024, then rose by 7.06% to $1.7 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $1.7 million, -$168000.0, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.